SIMILAR PATTERNS OF AMINO ACIDS FOR 3QXV_A_MTXA2000

List of similar pattern of amino acids derived from ASSAM search

Hit pattern: 3D amino acid arrangements similar to known drug binding site
Query pattern: Residues from known binding site for annotated drug that match the hit pattern

(Click link on the last column to view superposed patterns of amino acids in NGL viewer)
(Note that only 3-12 residue patterns can be used for ASSAM searches)

Filter list by:

	Hit	Macromolecule/ Organism	Pfam	Res.	Interface	HETATM	RMSD	Dali Z-score	Seq. Identity (%)
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	1i3u	ANTIBODY VHH LAMA DOMAIN (Lama glama)	PF07686 (V-set)	6	ALA A 24 ARG A 77 ASN A 79 VAL A 84 ALA A 103 TYR A 118	None None None None None CGN A 1 ( 4.0A)	0.86A	3qxvA-1i3uA: 21.0	3qxvA-1i3uA: 59.85
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	1kxt	IMMUNOGLOBULIN VHH FRAGMENT (Camelus dromedarius)	PF07686 (V-set)	6	VAL B 2 ALA B 24 MET B 34 ASN B 73 ALA B 94 TYR B 102	None	0.99A	3qxvA-1kxtB: 19.2	3qxvA-1kxtB: 68.75
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	1t66	IMMUNOGLOBULIN HEAVY CHAIN (Mus musculus)	no annotation	6	VAL H 2 ALA H 24 MET H 34 ARG H 74 VAL H 81 TYR H 107	None	0.86A	3qxvA-1t66H: 19.3	3qxvA-1t66H: 31.43
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	2fbj	IGA-KAPPA J539 FAB (HEAVY CHAIN) (Mus musculus)	PF07654 (C1-set) PF07686 (V-set)	6	VAL H 2 ALA H 24 MET H 34 ARG H 72 ASN H 74 TYR H 107	None	1.13A	3qxvA-2fbjH: 19.9	3qxvA-2fbjH: 31.53
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	2x6m	HEAVY CHAIN VARIABLE DOMAIN FROM DROMEDARY (Camelus dromedarius)	PF07686 (V-set)	6	ALA A 24 MET A 34 ASN A 75 VAL A 80 ALA A 99 TYR A 115	None	0.81A	3qxvA-2x6mA: 21.3	3qxvA-2x6mA: 70.54
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	2x6m	HEAVY CHAIN VARIABLE DOMAIN FROM DROMEDARY (Camelus dromedarius)	PF07686 (V-set)	6	MET A 34 ARG A 73 ASN A 75 VAL A 80 ALA A 99 TYR A 115	None	1.04A	3qxvA-2x6mA: 21.3	3qxvA-2x6mA: 70.54
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	2xa3	LLAMA HEAVY CHAIN ANTIBODY D7 (Lama glama)	PF07686 (V-set)	6	SER A 29 MET A 34 ASN A 73 VAL A 78 ALA A 94 TYR A 102	SO4 A1114 (-2.7A) None None None None None	0.90A	3qxvA-2xa3A: 21.0	3qxvA-2xa3A: 69.77
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	3g9a	MINIMIZER (Camelus dromedarius)	PF07686 (V-set)	6	ALA B 24 MET B 34 ARG B 71 VAL B 78 ALA B 94 TYR B 102	None	0.64A	3qxvA-3g9aB: 19.5	3qxvA-3g9aB: 64.93
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	3g9a	MINIMIZER (Camelus dromedarius)	PF07686 (V-set)	6	VAL B 2 ALA B 24 MET B 34 VAL B 78 ALA B 94 TYR B 102	None	0.87A	3qxvA-3g9aB: 19.5	3qxvA-3g9aB: 64.93
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	3k7u	ANTIBODY (Lama glama)	PF07686 (V-set)	6	MET A 34 ARG A 72 ASN A 74 VAL A 79 ALA A 98 TYR A 111	None	0.36A	3qxvA-3k7uA: 22.0	3qxvA-3k7uA: 73.81
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	3ln9	IMMUNOGLOBULIN HEAVY CHAIN ANTIBODY VARIABLE DOMAIN B10 (Camelidae)	PF07686 (V-set)	7	VAL A 2 ALA A 24 ARG A 72 ASN A 74 VAL A 79 ALA A 98 TYR A 113	None None None None None None GOL A 137 (-4.8A)	0.89A	3qxvA-3ln9A: 19.5	3qxvA-3ln9A: 67.94
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	3qxu	ANTI-METHOTREXATE CDR1-3 GRAFT (Lama glama)	PF07686 (V-set)	7	SER A 31 TRP A 34 MET A 36 ARG A 74 VAL A 81 ALA A 100 TYR A 120	None	1.41A	3qxvA-3qxuA: 24.2	3qxvA-3qxuA: 96.03
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	3qxu	ANTI-METHOTREXATE CDR1-3 GRAFT (Lama glama)	PF07686 (V-set)	7	VAL A 4 ALA A 26 SER A 30 MET A 36 VAL A 81 ALA A 100 TYR A 120	None	0.94A	3qxvA-3qxuA: 24.2	3qxvA-3qxuA: 96.03
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	3qxu	ANTI-METHOTREXATE CDR1-3 GRAFT (Lama glama)	PF07686 (V-set)	8	VAL A 4 ALA A 26 SER A 31 MET A 36 ARG A 74 VAL A 81 ALA A 100 TYR A 120	None	0.86A	3qxvA-3qxuA: 24.2	3qxvA-3qxuA: 96.03
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	3stb	SINGLE DOMAIN ANTIBODY VHH (Lama glama)	PF07686 (V-set)	6	ALA A 26 MET A 36 ARG A 73 ASN A 75 VAL A 80 ALA A 99	None	0.68A	3qxvA-3stbA: 22.1	3qxvA-3stbA: 70.77
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	3tpk	IMMUNOGLOBULIN HEAVY CHAIN ANTIBODY VARIABLE DOMAIN KW1 (Camelidae)	PF07686 (V-set)	6	VAL A 2 ALA A 24 ASN A 74 VAL A 79 ALA A 98 TYR A 110	None BEN A 133 (-3.6A) None BEN A 133 (-4.6A) BEN A 133 ( 4.2A) None	1.30A	3qxvA-3tpkA: 20.3	3qxvA-3tpkA: 64.06
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	3u0w	FAB HEAVY CHAIN, IG GAMMA-1 CHAIN C REGION (Homo sapiens; Mus musculus)	PF07654 (C1-set) PF07686 (V-set)	6	VAL H 2 ALA H 24 MET H 34 ARG H 72 ASN H 74 TYR H 102	None	1.05A	3qxvA-3u0wH: 19.8	3qxvA-3u0wH: 36.84
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	4dka	SINGLE DOMAIN ANTIBODY VHH (Lama glama)	PF07686 (V-set)	7	ALA A 24 MET A 34 ARG A 72 ASN A 74 VAL A 79 ALA A 98 TYR A 116	None	0.69A	3qxvA-4dkaA: 22.1	3qxvA-4dkaA: 73.23
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	4dka	SINGLE DOMAIN ANTIBODY VHH (Lama glama)	PF07686 (V-set)	7	ALA A 24 SER A 30 MET A 34 ARG A 72 ASN A 74 VAL A 79 ALA A 98	None	1.24A	3qxvA-4dkaA: 22.1	3qxvA-4dkaA: 73.23
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	4dka	SINGLE DOMAIN ANTIBODY VHH (Lama glama)	PF07686 (V-set)	7	VAL A 2 ALA A 24 MET A 34 ARG A 72 ASN A 74 VAL A 79 TYR A 116	None	0.91A	3qxvA-4dkaA: 22.1	3qxvA-4dkaA: 73.23
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	4eig	CA1698 CAMEL ANTIBODY FRAGMENT (Lama glama)	PF07686 (V-set)	7	ALA B 24 MET B 34 ARG B 71 ASN B 73 VAL B 78 ALA B 97 TYR B 106	None	0.76A	3qxvA-4eigB: 20.2	3qxvA-4eigB: 66.94
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	4ej1	NB113 CAMELID ANTIBODY FRAGMENT (Lama glama)	PF07686 (V-set)	5	MET C 34 ARG C 72 ASN C 74 VAL C 79 ALA C 98	None	0.34A	3qxvA-4ej1C: 21.6	3qxvA-4ej1C: 74.22
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	4fhb	NB179 (Lama glama)	PF07686 (V-set)	6	MET D 34 ARG D 72 ASN D 74 VAL D 79 ALA D 98 TYR D 118	None	0.58A	3qxvA-4fhbD: 21.2	3qxvA-4fhbD: 71.32
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	4gft	NANOBODY (Lama glama)	PF07686 (V-set)	6	MET B 36 ARG B 74 ASN B 76 VAL B 81 ALA B 100 TYR B 115	None None None None None PCA B 2 ( 3.9A)	0.32A	3qxvA-4gftB: 22.6	3qxvA-4gftB: 66.93
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	4glr	ANTI-PTAU HEAVY CHAIN (Gallus gallus)	PF07654 (C1-set) PF07686 (V-set)	5	VAL H 2 MET H 34 ARG H 71 ASN H 73 VAL H 78	None	0.52A	3qxvA-4glrH: 21.0	3qxvA-4glrH: 30.30
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	4hem	ANTI-BASEPLATE TP901-1 LLAMA VHH 02 (Lama glama)	PF07686 (V-set)	7	ALA E 24 MET E 34 ARG E 72 ASN E 74 VAL E 79 ALA E 98 TYR E 112	None	0.62A	3qxvA-4hemE: 23.0	3qxvA-4hemE: 73.39
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	4krm	NANOBODY/VHH DOMAIN 7D12 (Lama glama)	PF07686 (V-set)	6	MET B 34 ARG B 72 ASN B 74 VAL B 79 ALA B 98 TYR B 113	None	0.43A	3qxvA-4krmB: 23.5	3qxvA-4krmB: 70.16
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	4lhq	CAMELID NANOBODY (Vicugna pacos)	PF07686 (V-set)	6	ALA B 24 SER B 28 MET B 34 ARG B 72 ASN B 74 VAL B 79	None	0.87A	3qxvA-4lhqB: 21.7	3qxvA-4lhqB: 63.28
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	4mqt	NANOBODY 9-8 (Lama glama)	PF07686 (V-set)	6	VAL B 2 ALA B 24 ASN B 77 VAL B 82 ALA B 101 TYR B 110	None	0.92A	3qxvA-4mqtB: 19.0	3qxvA-4mqtB: 64.12
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	4n1h	CAMELID HEAVY-CHAIN ANTIBODY VARIABLE FRAGMENT CAB-F11N (Lama glama)	PF07686 (V-set)	5	MET B 34 ARG B 72 ASN B 74 VAL B 79 ALA B 98	None	0.47A	3qxvA-4n1hB: 21.5	3qxvA-4n1hB: 68.50
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	4nc1	A20.1 VHH (Lama glama)	PF07686 (V-set)	8	VAL C 9 ALA C 31 MET C 41 ARG C 79 ASN C 81 VAL C 86 ALA C 105 TYR C 119	None	0.90A	3qxvA-4nc1C: 21.7	3qxvA-4nc1C: 70.23
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	4nc2	B39 VHH (Lama glama)	PF07686 (V-set)	7	VAL B 2 ALA B 24 MET B 34 ARG B 71 ASN B 73 ALA B 97 TYR B 111	None	0.75A	3qxvA-4nc2B: 22.8	3qxvA-4nc2B: 70.16
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	4nik	SINGLE-CHAIN FV FRAGMENT ANTIBODY (Homo sapiens)	PF07686 (V-set)	6	VAL B 4 ALA B 26 MET B 36 ARG B 74 ASN B 76 TYR B 108	None	1.09A	3qxvA-4nikB: 20.3	3qxvA-4nikB: 32.13
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	4ocr	CAP256-VRC26.01 HEAVY CHAIN (Homo sapiens)	PF07654 (C1-set) PF07686 (V-set)	5	VAL H 2 MET H 34 ARG H 71 ASN H 73 VAL H 78	None	0.60A	3qxvA-4ocrH: 21.4	3qxvA-4ocrH: 54.05
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	4ouo	ANTI BLA G 1 SCFV (Gallus gallus)	PF07686 (V-set)	6	VAL A 116 ALA A 138 MET A 148 ARG A 185 ASN A 187 VAL A 192	None	0.87A	3qxvA-4ouoA: 20.6	3qxvA-4ouoA: 27.27
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	4p2c	NANOBODY 1, ANTI-F4+ETEC BACTERIA VHH VARIABLE REGION (Lama glama)	PF07686 (V-set)	7	VAL G 2 MET G 34 ARG G 71 ASN G 73 VAL G 78 ALA G 97 TYR G 111	None	0.58A	3qxvA-4p2cG: 18.9	3qxvA-4p2cG: 70.97
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	4p49	ANTIBODY SCFV B8 (Gallus gallus)	PF07686 (V-set)	6	VAL A 122 ALA A 144 MET A 154 ARG A 193 ASN A 195 VAL A 200	None	0.89A	3qxvA-4p49A: 21.7	3qxvA-4p49A: 51.88
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	4qlr	LLAMA NANOBODY N02 VH DOMAIN (Lama glama)	PF07686 (V-set)	6	ALA A 24 ARG A 72 ASN A 74 VAL A 79 ALA A 98 TYR A 113	None	0.73A	3qxvA-4qlrA: 22.2	3qxvA-4qlrA: 69.84
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	4qo1	NB139 NANOBODY AGAINST THE DNA-BINDING DOMAIN OF P53 (Lama glama)	PF07686 (V-set)	7	ALA A 25 MET A 35 ARG A 73 ASN A 75 VAL A 80 ALA A 99 TYR A 113	None	0.62A	3qxvA-4qo1A: 21.1	3qxvA-4qo1A: 62.70
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	4tvs	VHH DOMAIN BS-1 (Vicugna pacos)	PF05609 (LAP1C)	6	ALA a 25 ARG a 73 ASN a 75 VAL a 80 ALA a 99 TYR a 117	None	0.72A	3qxvA-4tvsa: 22.3	3qxvA-4tvsa: 72.87
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	4w6y	NANOBODY NBFEDF9 (Lama glama)	PF07686 (V-set)	6	MET B 34 ARG B 72 ASN B 74 VAL B 79 ALA B 98 TYR B 118	None None SO4 B 201 (-4.0A) None None None	1.47A	3qxvA-4w6yB: 21.1	3qxvA-4w6yB: 69.47
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	4w6y	NANOBODY NBFEDF9 (Lama glama)	PF07686 (V-set)	7	VAL B 2 ALA B 24 MET B 34 ASN B 74 VAL B 79 ALA B 98 TYR B 118	None None None SO4 B 201 (-4.0A) None None None	0.97A	3qxvA-4w6yB: 21.1	3qxvA-4w6yB: 69.47
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	4weu	ANTI-F4+ETEC BACTERIA VHH VARIABLE REGION (Lama glama)	PF07686 (V-set)	7	VAL D 802 ALA D 824 MET D 834 ARG D 872 ASN D 874 ALA D 898 TYR D 910	None	0.66A	3qxvA-4weuD: 22.1	3qxvA-4weuD: 72.00
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	4xt1	NANOBODY 7 (Vicugna pacos)	PF07686 (V-set)	7	VAL C 2 ALA C 24 MET C 34 ASN C 73 VAL C 78 ALA C 97 TYR C 107	None	0.92A	3qxvA-4xt1C: 18.9	3qxvA-4xt1C: 68.75
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	4y5v	DIABODY 305 VH DOMAIN (Homo sapiens)	PF07686 (V-set)	5	VAL A 2 MET A 34 ARG A 72 ASN A 74 VAL A 79	None	0.46A	3qxvA-4y5vA: 20.7	3qxvA-4y5vA: 66.67
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	4ybq	ANTIBODY FV FRAGMENT HEAVY CHAIN (Mus musculus)	PF07686 (V-set)	6	VAL D 3 ALA D 25 MET D 35 ARG D 73 ASN D 75 TYR D 109	None	1.02A	3qxvA-4ybqD: 20.9	3qxvA-4ybqD: 58.73
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	4yga	VHH-1B7 (Vicugna pacos)	PF07686 (V-set)	6	VAL B 3 ALA B 25 ARG B 73 ASN B 75 VAL B 80 ALA B 99	None	0.75A	3qxvA-4ygaB: 20.2	3qxvA-4ygaB: 60.32
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	5a2k	IG LAMBDA-1 CHAIN V REGION S43 (Mus musculus)	PF07686 (V-set)	6	VAL H 2 ALA H 24 MET H 34 ARG H 71 VAL H 78 TYR H 102	None	0.77A	3qxvA-5a2kH: 19.9	3qxvA-5a2kH: 29.03
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	5aum	HEAVY CHAIN OF FAB FRAGMENT (Rattus)	no annotation	6	VAL H 2 ALA H 24 MET H 34 ARG H 71 VAL H 78 ALA H 94	None	0.63A	3qxvA-5aumH: 19.7	3qxvA-5aumH: 38.16
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	5b3n	ANTI-H4K20ME1_SCFV (Mus musculus)	PF07686 (V-set)	6	VAL A 4 ALA A 26 MET A 36 ARG A 74 ASN A 76 TYR A 112	None	1.09A	3qxvA-5b3nA: 20.6	3qxvA-5b3nA: 58.91
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	5bop	NANOBODY (Lama glama)	PF07686 (V-set)	5	MET A 34 ARG A 72 ASN A 74 VAL A 79 ALA A 98	None	0.48A	3qxvA-5bopA: 22.3	3qxvA-5bopA: 69.60
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	5drz	HIV ANTIBODY F240 HEAVY CHAIN (Homo sapiens)	no annotation	5	VAL H 2 MET H 34 ARG H 71 ASN H 73 VAL H 78	None	0.55A	3qxvA-5drzH: 18.8	3qxvA-5drzH: 55.20
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	5e1h	F8(JOB10) VHH ANTIBODY (Vicugna pacos)	PF07686 (V-set)	6	VAL B 2 ALA B 24 MET B 34 ARG B 72 ASN B 74 VAL B 79	None	0.85A	3qxvA-5e1hB: 20.5	3qxvA-5e1hB: 68.75
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	5e7f	NANOBODY L06 (Camelus dromedarius)	PF07686 (V-set)	6	VAL A 4 ALA A 26 ARG A 73 ASN A 75 VAL A 80 ALA A 99	None	0.86A	3qxvA-5e7fA: 18.4	3qxvA-5e7fA: 66.93
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	5e7f	NANOBODY L06 (Camelus dromedarius)	PF07686 (V-set)	6	VAL A 4 MET A 36 ARG A 73 ASN A 75 VAL A 80 ALA A 99	None	0.66A	3qxvA-5e7fA: 18.4	3qxvA-5e7fA: 66.93
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	5f1k	NANOBODY MU1053 (Lama glama)	PF07686 (V-set)	5	MET C 34 ARG C 72 ASN C 74 VAL C 79 ALA C 98	None	0.46A	3qxvA-5f1kC: 22.0	3qxvA-5f1kC: 67.46
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	5f1o	NANOBODY MU551 (Lama glama)	PF07686 (V-set)	5	MET B 34 ARG B 72 ASN B 74 VAL B 79 ALA B 98	None	0.37A	3qxvA-5f1oB: 21.1	3qxvA-5f1oB: 65.91
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	5fwo	NANOBODY (Lama glama)	PF07686 (V-set)	8	VAL A 2 ALA A 24 MET A 34 ARG A 71 ASN A 73 VAL A 78 ALA A 94 TYR A 102	None	0.81A	3qxvA-5fwoA: 21.4	3qxvA-5fwoA: 68.18
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	5gxb	NANOBODY (Vicugna pacos)	PF07686 (V-set)	6	VAL B 2 ALA B 24 MET B 34 ASN B 74 VAL B 79 ALA B 98	None	0.89A	3qxvA-5gxbB: 20.7	3qxvA-5gxbB: 68.42
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	5gxb	NANOBODY (Vicugna pacos)	PF07686 (V-set)	6	VAL B 2 ALA B 24 MET B 34 VAL B 79 ALA B 98 TYR B 118	None	1.17A	3qxvA-5gxbB: 20.7	3qxvA-5gxbB: 68.42
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	5hvf	VHH-I83 (Vicugna pacos)	PF07686 (V-set)	7	VAL B 2 ALA B 24 ARG B 70 ASN B 72 VAL B 77 ALA B 96 TYR B 108	None	0.91A	3qxvA-5hvfB: 18.7	3qxvA-5hvfB: 69.35
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	5hvf	VHH-I83 (Vicugna pacos)	PF07686 (V-set)	7	VAL B 2 ALA B 24 MET B 34 ASN B 72 VAL B 77 ALA B 96 TYR B 108	None	1.10A	3qxvA-5hvfB: 18.7	3qxvA-5hvfB: 69.35
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	5iml	NANOBODY (Camelidae)	PF07686 (V-set)	6	ALA B 23 MET B 33 ASN B 73 VAL B 78 ALA B 97 TYR B 113	None	0.72A	3qxvA-5imlB: 23.7	3qxvA-5imlB: 75.40
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	5iml	NANOBODY (Camelidae)	PF07686 (V-set)	6	MET B 33 ARG B 71 ASN B 73 VAL B 78 ALA B 97 TYR B 113	None	0.30A	3qxvA-5imlB: 23.7	3qxvA-5imlB: 75.40
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	5j1s	VHH DOMAIN BS-2 (Vicugna pacos)	PF07686 (V-set)	7	ALA C 25 MET C 35 ARG C 72 ASN C 74 VAL C 79 ALA C 98 TYR C 112	None	0.86A	3qxvA-5j1sC: 19.3	3qxvA-5j1sC: 66.17
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	5j1s	VHH DOMAIN BS-2 (Vicugna pacos)	PF07686 (V-set)	6	VAL C 3 ALA C 25 MET C 35 VAL C 79 ALA C 98 TYR C 112	None	0.71A	3qxvA-5j1sC: 19.3	3qxvA-5j1sC: 66.17
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	5j56	VHH SINGLE CHAIN ANTIBODY V1C7 (Vicugna pacos)	PF07686 (V-set)	6	ALA B 24 ARG B 76 ASN B 78 VAL B 83 ALA B 102 TYR B 117	None	0.91A	3qxvA-5j56B: 20.6	3qxvA-5j56B: 67.18
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	5j56	VHH SINGLE CHAIN ANTIBODY V1C7 (Vicugna pacos)	PF07686 (V-set)	6	VAL B 2 ALA B 24 ARG B 76 ASN B 78 VAL B 83 TYR B 117	None	1.18A	3qxvA-5j56B: 20.6	3qxvA-5j56B: 67.18
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	5j57	VHH SINGLE CHAIN ANTIBODY V5E1 (Vicugna pacos)	PF07686 (V-set)	5	ALA B 24 ARG B 72 ASN B 74 VAL B 79 ALA B 98	None	0.44A	3qxvA-5j57B: 20.5	3qxvA-5j57B: 65.60
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	5ja8	NANOBODY 2 (Lama glama)	PF07686 (V-set)	5	ALA B 25 ARG B 73 ASN B 75 VAL B 80 ALA B 99	None	0.54A	3qxvA-5ja8B: 20.2	3qxvA-5ja8B: 70.16
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	5ja9	NANOBODY 6 (Lama glama)	PF07686 (V-set)	6	VAL A 3 ALA A 25 MET A 35 ARG A 73 ASN A 75 ALA A 99	None	0.88A	3qxvA-5ja9A: 20.2	3qxvA-5ja9A: 68.55
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	5lhq	CAMELID-DERIVED ANTIBODY FRAGMENT NB7 (Vicugna pacos)	PF07686 (V-set)	7	VAL B 2 ALA B 24 ARG B 72 ASN B 74 VAL B 79 ALA B 98 TYR B 122	None	0.60A	3qxvA-5lhqB: 21.6	3qxvA-5lhqB: 64.66
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	5lhr	CAMELID-DERIVED ANTIBODY FRAGMENT NB22 (Vicugna pacos)	PF07686 (V-set)	6	MET B 34 ARG B 72 ASN B 74 VAL B 79 ALA B 98 TYR B 110	None	1.29A	3qxvA-5lhrB: 20.1	3qxvA-5lhrB: 76.00
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	5lmj	NANOBODY (Lama glama)	PF07686 (V-set)	7	ALA A 24 MET A 34 ARG A 71 ASN A 73 VAL A 78 ALA A 94 TYR A 102	None	0.94A	3qxvA-5lmjA: 20.2	3qxvA-5lmjA: 73.23
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	5lmj	NANOBODY (Lama glama)	PF07686 (V-set)	7	VAL A 2 ALA A 24 ARG A 71 ASN A 73 VAL A 78 ALA A 94 TYR A 102	None	0.90A	3qxvA-5lmjA: 20.2	3qxvA-5lmjA: 73.23
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	5lwf	CAMELID HEAVY-CHAIN ANTIBODY VARIABLE FRAGMENT CAB-G10S (Lama glama)	no annotation	8	VAL C 5 ALA C 27 MET C 37 ARG C 75 ASN C 77 VAL C 82 ALA C 101 TYR C 117	None None None None None None None ACT C 202 (-4.4A)	0.74A	3qxvA-5lwfC: 21.4	3qxvA-5lwfC: 68.80
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	5nqw	026 (Lama glama)	no annotation	6	VAL C 3 ALA C 25 MET C 35 ARG C 73 ASN C 75 TYR C 112	None	1.10A	3qxvA-5nqwC: 21.1	3qxvA-5nqwC: 44.63
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	5o02	NANOBODY (VHH) NANO-4 (Vicugna pacos)	PF07686 (V-set)	6	VAL C 2 ALA C 24 ARG C 72 ASN C 74 ALA C 98 TYR C 113	None	0.87A	3qxvA-5o02C: 21.2	3qxvA-5o02C: 68.55
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	5o02	NANOBODY (VHH) NANO-4 (Vicugna pacos)	PF07686 (V-set)	6	VAL C 2 MET C 34 ARG C 72 ASN C 74 ALA C 98 TYR C 113	None	0.51A	3qxvA-5o02C: 21.2	3qxvA-5o02C: 68.55
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	5o04	NANOBODY (VHH) NANO-26 (Vicugna pacos)	PF07686 (V-set)	6	VAL E 2 ALA E 24 ARG E 71 ASN E 73 VAL E 78 TYR E 104	None	0.75A	3qxvA-5o04E: 18.6	3qxvA-5o04E: 65.32
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	5o8f	NANOBODY NB25 (Lama glama)	no annotation	6	MET L 34 ARG L 72 ASN L 74 VAL L 79 ALA L 98 TYR L 114	None	0.64A	3qxvA-5o8fL: 21.6	3qxvA-5o8fL: 68.46
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	5ovw	NANOBODY (Lama glama)	no annotation	5	ALA G 46 ARG G 94 ASN G 96 VAL G 101 ALA G 120	None	0.53A	3qxvA-5ovwG: 21.5	3qxvA-5ovwG: 59.57
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	5uk4	ANTI-VESICULAR STOMATITIS VIRUS N VHH (Vicugna pacos)	no annotation	7	VAL p 2 MET p 34 ARG p 72 ASN p 74 VAL p 79 ALA p 98 TYR p 114	None	0.65A	3qxvA-5uk4p: 21.3	3qxvA-5uk4p: 71.43
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	5vaq	NB914 (Lama glama)	no annotation	6	ALA B 24 SER B 30 ARG B 72 ASN B 74 VAL B 79 ALA B 98	None	1.02A	3qxvA-5vaqB: 22.8	3qxvA-5vaqB: 75.00
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	5vxj	SINGLE-DOMAIN ANTIBODY JMK-E3 (Vicugna pacos)	no annotation	6	VAL B 2 MET B 34 ARG B 72 ASN B 74 VAL B 79 ALA B 98	None	0.72A	3qxvA-5vxjB: 19.3	3qxvA-5vxjB: 63.08
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	5vxj	SINGLE-DOMAIN ANTIBODY JMK-E3 (Vicugna pacos)	no annotation	6	VAL B 2 MET B 34 ARG B 72 VAL B 79 ALA B 98 TYR B 108	None	0.82A	3qxvA-5vxjB: 19.3	3qxvA-5vxjB: 63.08
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	5vxl	SINGLE-DOMAIN ANTIBODY JPS-G3 (Vicugna pacos)	no annotation	7	ALA B 24 MET B 34 ARG B 73 ASN B 75 VAL B 80 ALA B 99 TYR B 106	None	0.68A	3qxvA-5vxlB: 20.2	3qxvA-5vxlB: 66.41
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	5wb1	ENVELOPE PROTEIN US28, NANOBODY 7 FUSION PROTEIN (Human betaherpesvirus 5; Lama glama)	no annotation	7	VAL A1002 ALA A1024 MET A1034 ASN A1073 VAL A1078 ALA A1097 TYR A1107	None	0.97A	3qxvA-5wb1A: 18.0	3qxvA-5wb1A: 15.08
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	5y9f	HEAVY CHAIN OF FAB FRAGMENT OF ANTIBODY 28F10 (Mus musculus)	no annotation	6	VAL L 2 ALA L 24 MET L 34 ARG L 72 ASN L 74 TYR L 112	None	0.93A	3qxvA-5y9fL: 20.1	3qxvA-5y9fL: 57.94
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	5yy5	- (-)	no annotation	6	VAL C 2 ALA C 24 MET C 34 ARG C 71 ASN C 73 TYR C 97	None	0.92A	3qxvA-5yy5C: 19.4	3qxvA-5yy5C: undetectable
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	6apq	ANTI-MARBURGVIRUS NUCLEOPROTEIN SINGLE DOMAIN ANTIBODY B (Lama glama)	no annotation	6	VAL A 2 ALA A 24 ARG A 71 ASN A 73 VAL A 78 TYR A 107	None CL A 202 ( 4.0A) None None None None	1.19A	3qxvA-6apqA: 19.2	3qxvA-6apqA: 66.93
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	6c9w	- (-)	no annotation	6	VAL B 2 ALA B 24 MET B 34 ASN B 74 VAL B 79 TYR B 114	None	1.17A	3qxvA-6c9wB: 21.1	3qxvA-6c9wB: undetectable
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	6d11	1450 ANTIBODY, HEAVY CHAIN (Homo sapiens)	no annotation	5	VAL A 2 MET A 34 ARG A 71 ASN A 73 VAL A 78	None	0.51A	3qxvA-6d11A: 20.4	3qxvA-6d11A: 44.72
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	6dbe	NANOBODY VHH R303 (Lama glama)	no annotation	6	SER A 30 MET A 34 ARG A 72 VAL A 79 ALA A 98 TYR A 107	None	1.26A	3qxvA-6dbeA: 20.6	3qxvA-6dbeA: undetectable
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	6dbe	NANOBODY VHH R303 (Lama glama)	no annotation	6	VAL A 2 ALA A 24 MET A 34 ASN A 74 ALA A 98 TYR A 107	None	1.13A	3qxvA-6dbeA: 20.6	3qxvA-6dbeA: undetectable
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	6dbe	NANOBODY VHH R303 (Lama glama)	no annotation	6	VAL A 2 ALA A 24 MET A 34 VAL A 79 ALA A 98 TYR A 107	None	0.81A	3qxvA-6dbeA: 20.6	3qxvA-6dbeA: undetectable
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	6dbe	NANOBODY VHH R303 (Lama glama)	no annotation	6	VAL A 2 SER A 30 MET A 34 VAL A 79 ALA A 98 TYR A 107	None	1.01A	3qxvA-6dbeA: 20.6	3qxvA-6dbeA: undetectable
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	6ehg	HC3NB1 (Lama glama)	no annotation	7	ALA C 24 MET C 34 ARG C 72 ASN C 74 VAL C 79 ALA C 98 TYR C 112	None	0.71A	3qxvA-6ehgC: 22.2	3qxvA-6ehgC: 57.14
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	6gzp	NANOBODY (Lama glama)	no annotation	7	VAL A 2 ALA A 24 MET A 34 ARG A 71 ASN A 73 ALA A 94 TYR A 102	None	0.71A	3qxvA-6gzpA: 21.6	3qxvA-6gzpA: undetectable
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	8fab	IGG1-LAMBDA HIL FAB (HEAVY CHAIN) (Homo sapiens)	PF07654 (C1-set) PF07686 (V-set)	6	VAL B 2 ALA B 24 MET B 34 ARG B 72 ASN B 74 TYR B 110	None	1.02A	3qxvA-8fabB: 21.7	3qxvA-8fabB: 59.52

[["3QXV_A_MTXA2000_1","1i3u","Lama glama","ANTIBODY VHH LAMA DOMAIN","PF07686(V-set)",6,"ALA A  24;ARG A  77;ASN A  79;VAL A  84;ALA A 103;TYR A 118","None;None;None;None;None;CGN A   1 ( 4.0A)","0.86A","3qxvA-1i3uA:21.0","3qxvA-1i3uA:59.85"],["3QXV_A_MTXA2000_1","1kxt","Camelus dromedarius","IMMUNOGLOBULIN VHH FRAGMENT","PF07686(V-set)",6,"VAL B   2;ALA B  24;MET B  34;ASN B  73;ALA B  94;TYR B 102","None","0.99A","3qxvA-1kxtB:19.2","3qxvA-1kxtB:68.75"],["3QXV_A_MTXA2000_1","1t66","Mus musculus","IMMUNOGLOBULIN HEAVY CHAIN","no annotation",6,"VAL H   2;ALA H  24;MET H  34;ARG H  74;VAL H  81;TYR H 107","None","0.86A","3qxvA-1t66H:19.3","3qxvA-1t66H:31.43"],["3QXV_A_MTXA2000_1","2fbj","Mus musculus","IGA-KAPPA J539 FAB (HEAVY CHAIN)","PF07654(C1-set);PF07686(V-set)",6,"VAL H   2;ALA H  24;MET H  34;ARG H  72;ASN H  74;TYR H 107","None","1.13A","3qxvA-2fbjH:19.9","3qxvA-2fbjH:31.53"],["3QXV_A_MTXA2000_1","2x6m","Camelus dromedarius","HEAVY CHAIN VARIABLE DOMAIN FROM DROMEDARY","PF07686(V-set)",6,"ALA A  24;MET A  34;ASN A  75;VAL A  80;ALA A  99;TYR A 115","None","0.81A","3qxvA-2x6mA:21.3","3qxvA-2x6mA:70.54"],["3QXV_A_MTXA2000_1","2x6m","Camelus dromedarius","HEAVY CHAIN VARIABLE DOMAIN FROM DROMEDARY","PF07686(V-set)",6,"MET A  34;ARG A  73;ASN A  75;VAL A  80;ALA A  99;TYR A 115","None","1.04A","3qxvA-2x6mA:21.3","3qxvA-2x6mA:70.54"],["3QXV_A_MTXA2000_1","2xa3","Lama glama","LLAMA HEAVY CHAIN ANTIBODY D7","PF07686(V-set)",6,"SER A  29;MET A  34;ASN A  73;VAL A  78;ALA A  94;TYR A 102","SO4 A1114 (-2.7A);None;None;None;None;None","0.90A","3qxvA-2xa3A:21.0","3qxvA-2xa3A:69.77"],["3QXV_A_MTXA2000_1","3g9a","Camelus dromedarius","MINIMIZER","PF07686(V-set)",6,"ALA B  24;MET B  34;ARG B  71;VAL B  78;ALA B  94;TYR B 102","None","0.64A","3qxvA-3g9aB:19.5","3qxvA-3g9aB:64.93"],["3QXV_A_MTXA2000_1","3g9a","Camelus dromedarius","MINIMIZER","PF07686(V-set)",6,"VAL B   2;ALA B  24;MET B  34;VAL B  78;ALA B  94;TYR B 102","None","0.87A","3qxvA-3g9aB:19.5","3qxvA-3g9aB:64.93"],["3QXV_A_MTXA2000_1","3k7u","Lama glama","ANTIBODY","PF07686(V-set)",6,"MET A  34;ARG A  72;ASN A  74;VAL A  79;ALA A  98;TYR A 111","None","0.36A","3qxvA-3k7uA:22.0","3qxvA-3k7uA:73.81"],["3QXV_A_MTXA2000_1","3ln9","Camelidae","IMMUNOGLOBULIN HEAVY CHAIN ANTIBODY VARIABLE DOMAIN B10","PF07686(V-set)",7,"VAL A   2;ALA A  24;ARG A  72;ASN A  74;VAL A  79;ALA A  98;TYR A 113","None;None;None;None;None;None;GOL A 137 (-4.8A)","0.89A","3qxvA-3ln9A:19.5","3qxvA-3ln9A:67.94"],["3QXV_A_MTXA2000_1","3qxu","Lama glama","ANTI-METHOTREXATE CDR1-3 GRAFT","PF07686(V-set)",7,"SER A  31;TRP A  34;MET A  36;ARG A  74;VAL A  81;ALA A 100;TYR A 120","None","1.41A","3qxvA-3qxuA:24.2","3qxvA-3qxuA:96.03"],["3QXV_A_MTXA2000_1","3qxu","Lama glama","ANTI-METHOTREXATE CDR1-3 GRAFT","PF07686(V-set)",7,"VAL A   4;ALA A  26;SER A  30;MET A  36;VAL A  81;ALA A 100;TYR A 120","None","0.94A","3qxvA-3qxuA:24.2","3qxvA-3qxuA:96.03"],["3QXV_A_MTXA2000_1","3qxu","Lama glama","ANTI-METHOTREXATE CDR1-3 GRAFT","PF07686(V-set)",8,"VAL A   4;ALA A  26;SER A  31;MET A  36;ARG A  74;VAL A  81;ALA A 100;TYR A 120","None","0.86A","3qxvA-3qxuA:24.2","3qxvA-3qxuA:96.03"],["3QXV_A_MTXA2000_1","3stb","Lama glama","SINGLE DOMAIN ANTIBODY VHH","PF07686(V-set)",6,"ALA A  26;MET A  36;ARG A  73;ASN A  75;VAL A  80;ALA A  99","None","0.68A","3qxvA-3stbA:22.1","3qxvA-3stbA:70.77"],["3QXV_A_MTXA2000_1","3tpk","Camelidae","IMMUNOGLOBULIN HEAVY CHAIN ANTIBODY VARIABLE DOMAIN KW1","PF07686(V-set)",6,"VAL A   2;ALA A  24;ASN A  74;VAL A  79;ALA A  98;TYR A 110","None;BEN A 133 (-3.6A);None;BEN A 133 (-4.6A);BEN A 133 ( 4.2A);None","1.30A","3qxvA-3tpkA:20.3","3qxvA-3tpkA:64.06"],["3QXV_A_MTXA2000_1","3u0w","Homo sapiens;Mus musculus","FAB HEAVY CHAIN, IG GAMMA-1 CHAIN C REGION","PF07654(C1-set);PF07686(V-set)",6,"VAL H   2;ALA H  24;MET H  34;ARG H  72;ASN H  74;TYR H 102","None","1.05A","3qxvA-3u0wH:19.8","3qxvA-3u0wH:36.84"],["3QXV_A_MTXA2000_1","4dka","Lama glama","SINGLE DOMAIN ANTIBODY VHH","PF07686(V-set)",7,"ALA A  24;MET A  34;ARG A  72;ASN A  74;VAL A  79;ALA A  98;TYR A 116","None","0.69A","3qxvA-4dkaA:22.1","3qxvA-4dkaA:73.23"],["3QXV_A_MTXA2000_1","4dka","Lama glama","SINGLE DOMAIN ANTIBODY VHH","PF07686(V-set)",7,"ALA A  24;SER A  30;MET A  34;ARG A  72;ASN A  74;VAL A  79;ALA A  98","None","1.24A","3qxvA-4dkaA:22.1","3qxvA-4dkaA:73.23"],["3QXV_A_MTXA2000_1","4dka","Lama glama","SINGLE DOMAIN ANTIBODY VHH","PF07686(V-set)",7,"VAL A   2;ALA A  24;MET A  34;ARG A  72;ASN A  74;VAL A  79;TYR A 116","None","0.91A","3qxvA-4dkaA:22.1","3qxvA-4dkaA:73.23"],["3QXV_A_MTXA2000_1","4eig","Lama glama","CA1698 CAMEL ANTIBODY FRAGMENT","PF07686(V-set)",7,"ALA B  24;MET B  34;ARG B  71;ASN B  73;VAL B  78;ALA B  97;TYR B 106","None","0.76A","3qxvA-4eigB:20.2","3qxvA-4eigB:66.94"],["3QXV_A_MTXA2000_1","4ej1","Lama glama","NB113 CAMELID ANTIBODY FRAGMENT","PF07686(V-set)",5,"MET C  34;ARG C  72;ASN C  74;VAL C  79;ALA C  98","None","0.34A","3qxvA-4ej1C:21.6","3qxvA-4ej1C:74.22"],["3QXV_A_MTXA2000_1","4fhb","Lama glama","NB179","PF07686(V-set)",6,"MET D  34;ARG D  72;ASN D  74;VAL D  79;ALA D  98;TYR D 118","None","0.58A","3qxvA-4fhbD:21.2","3qxvA-4fhbD:71.32"],["3QXV_A_MTXA2000_1","4gft","Lama glama","NANOBODY","PF07686(V-set)",6,"MET B  36;ARG B  74;ASN B  76;VAL B  81;ALA B 100;TYR B 115","None;None;None;None;None;PCA B   2 ( 3.9A)","0.32A","3qxvA-4gftB:22.6","3qxvA-4gftB:66.93"],["3QXV_A_MTXA2000_1","4glr","Gallus gallus","ANTI-PTAU HEAVY CHAIN","PF07654(C1-set);PF07686(V-set)",5,"VAL H   2;MET H  34;ARG H  71;ASN H  73;VAL H  78","None","0.52A","3qxvA-4glrH:21.0","3qxvA-4glrH:30.30"],["3QXV_A_MTXA2000_1","4hem","Lama glama","ANTI-BASEPLATE TP901-1 LLAMA VHH 02","PF07686(V-set)",7,"ALA E  24;MET E  34;ARG E  72;ASN E  74;VAL E  79;ALA E  98;TYR E 112","None","0.62A","3qxvA-4hemE:23.0","3qxvA-4hemE:73.39"],["3QXV_A_MTXA2000_1","4krm","Lama glama","NANOBODY\/VHH DOMAIN 7D12","PF07686(V-set)",6,"MET B  34;ARG B  72;ASN B  74;VAL B  79;ALA B  98;TYR B 113","None","0.43A","3qxvA-4krmB:23.5","3qxvA-4krmB:70.16"],["3QXV_A_MTXA2000_1","4lhq","Vicugna pacos","CAMELID NANOBODY","PF07686(V-set)",6,"ALA B  24;SER B  28;MET B  34;ARG B  72;ASN B  74;VAL B  79","None","0.87A","3qxvA-4lhqB:21.7","3qxvA-4lhqB:63.28"],["3QXV_A_MTXA2000_1","4mqt","Lama glama","NANOBODY 9-8","PF07686(V-set)",6,"VAL B   2;ALA B  24;ASN B  77;VAL B  82;ALA B 101;TYR B 110","None","0.92A","3qxvA-4mqtB:19.0","3qxvA-4mqtB:64.12"],["3QXV_A_MTXA2000_1","4n1h","Lama glama","CAMELID HEAVY-CHAIN ANTIBODY VARIABLE FRAGMENT CAB-F11N","PF07686(V-set)",5,"MET B  34;ARG B  72;ASN B  74;VAL B  79;ALA B  98","None","0.47A","3qxvA-4n1hB:21.5","3qxvA-4n1hB:68.50"],["3QXV_A_MTXA2000_1","4nc1","Lama glama","A20.1 VHH","PF07686(V-set)",8,"VAL C   9;ALA C  31;MET C  41;ARG C  79;ASN C  81;VAL C  86;ALA C 105;TYR C 119","None","0.90A","3qxvA-4nc1C:21.7","3qxvA-4nc1C:70.23"],["3QXV_A_MTXA2000_1","4nc2","Lama glama","B39 VHH","PF07686(V-set)",7,"VAL B   2;ALA B  24;MET B  34;ARG B  71;ASN B  73;ALA B  97;TYR B 111","None","0.75A","3qxvA-4nc2B:22.8","3qxvA-4nc2B:70.16"],["3QXV_A_MTXA2000_1","4nik","Homo sapiens","SINGLE-CHAIN FV FRAGMENT ANTIBODY","PF07686(V-set)",6,"VAL B   4;ALA B  26;MET B  36;ARG B  74;ASN B  76;TYR B 108","None","1.09A","3qxvA-4nikB:20.3","3qxvA-4nikB:32.13"],["3QXV_A_MTXA2000_1","4ocr","Homo sapiens","CAP256-VRC26.01 HEAVY CHAIN","PF07654(C1-set);PF07686(V-set)",5,"VAL H   2;MET H  34;ARG H  71;ASN H  73;VAL H  78","None","0.60A","3qxvA-4ocrH:21.4","3qxvA-4ocrH:54.05"],["3QXV_A_MTXA2000_1","4ouo","Gallus gallus","ANTI BLA G 1 SCFV","PF07686(V-set)",6,"VAL A 116;ALA A 138;MET A 148;ARG A 185;ASN A 187;VAL A 192","None","0.87A","3qxvA-4ouoA:20.6","3qxvA-4ouoA:27.27"],["3QXV_A_MTXA2000_1","4p2c","Lama glama","NANOBODY 1, ANTI-F4+ETEC BACTERIA VHH VARIABLE REGION","PF07686(V-set)",7,"VAL G   2;MET G  34;ARG G  71;ASN G  73;VAL G  78;ALA G  97;TYR G 111","None","0.58A","3qxvA-4p2cG:18.9","3qxvA-4p2cG:70.97"],["3QXV_A_MTXA2000_1","4p49","Gallus gallus","ANTIBODY SCFV B8","PF07686(V-set)",6,"VAL A 122;ALA A 144;MET A 154;ARG A 193;ASN A 195;VAL A 200","None","0.89A","3qxvA-4p49A:21.7","3qxvA-4p49A:51.88"],["3QXV_A_MTXA2000_1","4qlr","Lama glama","LLAMA NANOBODY N02 VH DOMAIN","PF07686(V-set)",6,"ALA A  24;ARG A  72;ASN A  74;VAL A  79;ALA A  98;TYR A 113","None","0.73A","3qxvA-4qlrA:22.2","3qxvA-4qlrA:69.84"],["3QXV_A_MTXA2000_1","4qo1","Lama glama","NB139 NANOBODY AGAINST THE DNA-BINDING DOMAIN OF P53","PF07686(V-set)",7,"ALA A  25;MET A  35;ARG A  73;ASN A  75;VAL A  80;ALA A  99;TYR A 113","None","0.62A","3qxvA-4qo1A:21.1","3qxvA-4qo1A:62.70"],["3QXV_A_MTXA2000_1","4tvs","Vicugna pacos","VHH DOMAIN BS-1","PF05609(LAP1C)",6,"ALA a  25;ARG a  73;ASN a  75;VAL a  80;ALA a  99;TYR a 117","None","0.72A","3qxvA-4tvsa:22.3","3qxvA-4tvsa:72.87"],["3QXV_A_MTXA2000_1","4w6y","Lama glama","NANOBODY NBFEDF9","PF07686(V-set)",6,"MET B  34;ARG B  72;ASN B  74;VAL B  79;ALA B  98;TYR B 118","None;None;SO4 B 201 (-4.0A);None;None;None","1.47A","3qxvA-4w6yB:21.1","3qxvA-4w6yB:69.47"],["3QXV_A_MTXA2000_1","4w6y","Lama glama","NANOBODY NBFEDF9","PF07686(V-set)",7,"VAL B   2;ALA B  24;MET B  34;ASN B  74;VAL B  79;ALA B  98;TYR B 118","None;None;None;SO4 B 201 (-4.0A);None;None;None","0.97A","3qxvA-4w6yB:21.1","3qxvA-4w6yB:69.47"],["3QXV_A_MTXA2000_1","4weu","Lama glama","ANTI-F4+ETEC BACTERIA VHH VARIABLE REGION","PF07686(V-set)",7,"VAL D 802;ALA D 824;MET D 834;ARG D 872;ASN D 874;ALA D 898;TYR D 910","None","0.66A","3qxvA-4weuD:22.1","3qxvA-4weuD:72.00"],["3QXV_A_MTXA2000_1","4xt1","Vicugna pacos","NANOBODY 7","PF07686(V-set)",7,"VAL C   2;ALA C  24;MET C  34;ASN C  73;VAL C  78;ALA C  97;TYR C 107","None","0.92A","3qxvA-4xt1C:18.9","3qxvA-4xt1C:68.75"],["3QXV_A_MTXA2000_1","4y5v","Homo sapiens","DIABODY 305 VH DOMAIN","PF07686(V-set)",5,"VAL A   2;MET A  34;ARG A  72;ASN A  74;VAL A  79","None","0.46A","3qxvA-4y5vA:20.7","3qxvA-4y5vA:66.67"],["3QXV_A_MTXA2000_1","4ybq","Mus musculus","ANTIBODY FV FRAGMENT HEAVY CHAIN","PF07686(V-set)",6,"VAL D   3;ALA D  25;MET D  35;ARG D  73;ASN D  75;TYR D 109","None","1.02A","3qxvA-4ybqD:20.9","3qxvA-4ybqD:58.73"],["3QXV_A_MTXA2000_1","4yga","Vicugna pacos","VHH-1B7","PF07686(V-set)",6,"VAL B   3;ALA B  25;ARG B  73;ASN B  75;VAL B  80;ALA B  99","None","0.75A","3qxvA-4ygaB:20.2","3qxvA-4ygaB:60.32"],["3QXV_A_MTXA2000_1","5a2k","Mus musculus","IG LAMBDA-1 CHAIN V REGION S43","PF07686(V-set)",6,"VAL H   2;ALA H  24;MET H  34;ARG H  71;VAL H  78;TYR H 102","None","0.77A","3qxvA-5a2kH:19.9","3qxvA-5a2kH:29.03"],["3QXV_A_MTXA2000_1","5aum","Rattus","HEAVY CHAIN OF FAB FRAGMENT","no annotation",6,"VAL H   2;ALA H  24;MET H  34;ARG H  71;VAL H  78;ALA H  94","None","0.63A","3qxvA-5aumH:19.7","3qxvA-5aumH:38.16"],["3QXV_A_MTXA2000_1","5b3n","Mus musculus","ANTI-H4K20ME1_SCFV","PF07686(V-set)",6,"VAL A   4;ALA A  26;MET A  36;ARG A  74;ASN A  76;TYR A 112","None","1.09A","3qxvA-5b3nA:20.6","3qxvA-5b3nA:58.91"],["3QXV_A_MTXA2000_1","5bop","Lama glama","NANOBODY","PF07686(V-set)",5,"MET A  34;ARG A  72;ASN A  74;VAL A  79;ALA A  98","None","0.48A","3qxvA-5bopA:22.3","3qxvA-5bopA:69.60"],["3QXV_A_MTXA2000_1","5drz","Homo sapiens","HIV ANTIBODY F240 HEAVY CHAIN","no annotation",5,"VAL H   2;MET H  34;ARG H  71;ASN H  73;VAL H  78","None","0.55A","3qxvA-5drzH:18.8","3qxvA-5drzH:55.20"],["3QXV_A_MTXA2000_1","5e1h","Vicugna pacos","F8(JOB10) VHH ANTIBODY","PF07686(V-set)",6,"VAL B   2;ALA B  24;MET B  34;ARG B  72;ASN B  74;VAL B  79","None","0.85A","3qxvA-5e1hB:20.5","3qxvA-5e1hB:68.75"],["3QXV_A_MTXA2000_1","5e7f","Camelus dromedarius","NANOBODY L06","PF07686(V-set)",6,"VAL A   4;ALA A  26;ARG A  73;ASN A  75;VAL A  80;ALA A  99","None","0.86A","3qxvA-5e7fA:18.4","3qxvA-5e7fA:66.93"],["3QXV_A_MTXA2000_1","5e7f","Camelus dromedarius","NANOBODY L06","PF07686(V-set)",6,"VAL A   4;MET A  36;ARG A  73;ASN A  75;VAL A  80;ALA A  99","None","0.66A","3qxvA-5e7fA:18.4","3qxvA-5e7fA:66.93"],["3QXV_A_MTXA2000_1","5f1k","Lama glama","NANOBODY MU1053","PF07686(V-set)",5,"MET C  34;ARG C  72;ASN C  74;VAL C  79;ALA C  98","None","0.46A","3qxvA-5f1kC:22.0","3qxvA-5f1kC:67.46"],["3QXV_A_MTXA2000_1","5f1o","Lama glama","NANOBODY MU551","PF07686(V-set)",5,"MET B  34;ARG B  72;ASN B  74;VAL B  79;ALA B  98","None","0.37A","3qxvA-5f1oB:21.1","3qxvA-5f1oB:65.91"],["3QXV_A_MTXA2000_1","5fwo","Lama glama","NANOBODY","PF07686(V-set)",8,"VAL A   2;ALA A  24;MET A  34;ARG A  71;ASN A  73;VAL A  78;ALA A  94;TYR A 102","None","0.81A","3qxvA-5fwoA:21.4","3qxvA-5fwoA:68.18"],["3QXV_A_MTXA2000_1","5gxb","Vicugna pacos","NANOBODY","PF07686(V-set)",6,"VAL B   2;ALA B  24;MET B  34;ASN B  74;VAL B  79;ALA B  98","None","0.89A","3qxvA-5gxbB:20.7","3qxvA-5gxbB:68.42"],["3QXV_A_MTXA2000_1","5gxb","Vicugna pacos","NANOBODY","PF07686(V-set)",6,"VAL B   2;ALA B  24;MET B  34;VAL B  79;ALA B  98;TYR B 118","None","1.17A","3qxvA-5gxbB:20.7","3qxvA-5gxbB:68.42"],["3QXV_A_MTXA2000_1","5hvf","Vicugna pacos","VHH-I83","PF07686(V-set)",7,"VAL B   2;ALA B  24;ARG B  70;ASN B  72;VAL B  77;ALA B  96;TYR B 108","None","0.91A","3qxvA-5hvfB:18.7","3qxvA-5hvfB:69.35"],["3QXV_A_MTXA2000_1","5hvf","Vicugna pacos","VHH-I83","PF07686(V-set)",7,"VAL B   2;ALA B  24;MET B  34;ASN B  72;VAL B  77;ALA B  96;TYR B 108","None","1.10A","3qxvA-5hvfB:18.7","3qxvA-5hvfB:69.35"],["3QXV_A_MTXA2000_1","5iml","Camelidae","NANOBODY","PF07686(V-set)",6,"ALA B  23;MET B  33;ASN B  73;VAL B  78;ALA B  97;TYR B 113","None","0.72A","3qxvA-5imlB:23.7","3qxvA-5imlB:75.40"],["3QXV_A_MTXA2000_1","5iml","Camelidae","NANOBODY","PF07686(V-set)",6,"MET B  33;ARG B  71;ASN B  73;VAL B  78;ALA B  97;TYR B 113","None","0.30A","3qxvA-5imlB:23.7","3qxvA-5imlB:75.40"],["3QXV_A_MTXA2000_1","5j1s","Vicugna pacos","VHH DOMAIN BS-2","PF07686(V-set)",7,"ALA C  25;MET C  35;ARG C  72;ASN C  74;VAL C  79;ALA C  98;TYR C 112","None","0.86A","3qxvA-5j1sC:19.3","3qxvA-5j1sC:66.17"],["3QXV_A_MTXA2000_1","5j1s","Vicugna pacos","VHH DOMAIN BS-2","PF07686(V-set)",6,"VAL C   3;ALA C  25;MET C  35;VAL C  79;ALA C  98;TYR C 112","None","0.71A","3qxvA-5j1sC:19.3","3qxvA-5j1sC:66.17"],["3QXV_A_MTXA2000_1","5j56","Vicugna pacos","VHH SINGLE CHAIN ANTIBODY V1C7","PF07686(V-set)",6,"ALA B  24;ARG B  76;ASN B  78;VAL B  83;ALA B 102;TYR B 117","None","0.91A","3qxvA-5j56B:20.6","3qxvA-5j56B:67.18"],["3QXV_A_MTXA2000_1","5j56","Vicugna pacos","VHH SINGLE CHAIN ANTIBODY V1C7","PF07686(V-set)",6,"VAL B   2;ALA B  24;ARG B  76;ASN B  78;VAL B  83;TYR B 117","None","1.18A","3qxvA-5j56B:20.6","3qxvA-5j56B:67.18"],["3QXV_A_MTXA2000_1","5j57","Vicugna pacos","VHH SINGLE CHAIN ANTIBODY V5E1","PF07686(V-set)",5,"ALA B  24;ARG B  72;ASN B  74;VAL B  79;ALA B  98","None","0.44A","3qxvA-5j57B:20.5","3qxvA-5j57B:65.60"],["3QXV_A_MTXA2000_1","5ja8","Lama glama","NANOBODY 2","PF07686(V-set)",5,"ALA B  25;ARG B  73;ASN B  75;VAL B  80;ALA B  99","None","0.54A","3qxvA-5ja8B:20.2","3qxvA-5ja8B:70.16"],["3QXV_A_MTXA2000_1","5ja9","Lama glama","NANOBODY 6","PF07686(V-set)",6,"VAL A   3;ALA A  25;MET A  35;ARG A  73;ASN A  75;ALA A  99","None","0.88A","3qxvA-5ja9A:20.2","3qxvA-5ja9A:68.55"],["3QXV_A_MTXA2000_1","5lhq","Vicugna pacos","CAMELID-DERIVED ANTIBODY FRAGMENT NB7","PF07686(V-set)",7,"VAL B   2;ALA B  24;ARG B  72;ASN B  74;VAL B  79;ALA B  98;TYR B 122","None","0.60A","3qxvA-5lhqB:21.6","3qxvA-5lhqB:64.66"],["3QXV_A_MTXA2000_1","5lhr","Vicugna pacos","CAMELID-DERIVED ANTIBODY FRAGMENT NB22","PF07686(V-set)",6,"MET B  34;ARG B  72;ASN B  74;VAL B  79;ALA B  98;TYR B 110","None","1.29A","3qxvA-5lhrB:20.1","3qxvA-5lhrB:76.00"],["3QXV_A_MTXA2000_1","5lmj","Lama glama","NANOBODY","PF07686(V-set)",7,"ALA A  24;MET A  34;ARG A  71;ASN A  73;VAL A  78;ALA A  94;TYR A 102","None","0.94A","3qxvA-5lmjA:20.2","3qxvA-5lmjA:73.23"],["3QXV_A_MTXA2000_1","5lmj","Lama glama","NANOBODY","PF07686(V-set)",7,"VAL A   2;ALA A  24;ARG A  71;ASN A  73;VAL A  78;ALA A  94;TYR A 102","None","0.90A","3qxvA-5lmjA:20.2","3qxvA-5lmjA:73.23"],["3QXV_A_MTXA2000_1","5lwf","Lama glama","CAMELID HEAVY-CHAIN ANTIBODY VARIABLE FRAGMENT CAB-G10S","no annotation",8,"VAL C   5;ALA C  27;MET C  37;ARG C  75;ASN C  77;VAL C  82;ALA C 101;TYR C 117","None;None;None;None;None;None;None;ACT C 202 (-4.4A)","0.74A","3qxvA-5lwfC:21.4","3qxvA-5lwfC:68.80"],["3QXV_A_MTXA2000_1","5nqw","Lama glama","026","no annotation",6,"VAL C   3;ALA C  25;MET C  35;ARG C  73;ASN C  75;TYR C 112","None","1.10A","3qxvA-5nqwC:21.1","3qxvA-5nqwC:44.63"],["3QXV_A_MTXA2000_1","5o02","Vicugna pacos","NANOBODY (VHH) NANO-4","PF07686(V-set)",6,"VAL C   2;ALA C  24;ARG C  72;ASN C  74;ALA C  98;TYR C 113","None","0.87A","3qxvA-5o02C:21.2","3qxvA-5o02C:68.55"],["3QXV_A_MTXA2000_1","5o02","Vicugna pacos","NANOBODY (VHH) NANO-4","PF07686(V-set)",6,"VAL C   2;MET C  34;ARG C  72;ASN C  74;ALA C  98;TYR C 113","None","0.51A","3qxvA-5o02C:21.2","3qxvA-5o02C:68.55"],["3QXV_A_MTXA2000_1","5o04","Vicugna pacos","NANOBODY (VHH) NANO-26","PF07686(V-set)",6,"VAL E   2;ALA E  24;ARG E  71;ASN E  73;VAL E  78;TYR E 104","None","0.75A","3qxvA-5o04E:18.6","3qxvA-5o04E:65.32"],["3QXV_A_MTXA2000_1","5o8f","Lama glama","NANOBODY NB25","no annotation",6,"MET L  34;ARG L  72;ASN L  74;VAL L  79;ALA L  98;TYR L 114","None","0.64A","3qxvA-5o8fL:21.6","3qxvA-5o8fL:68.46"],["3QXV_A_MTXA2000_1","5ovw","Lama glama","NANOBODY","no annotation",5,"ALA G  46;ARG G  94;ASN G  96;VAL G 101;ALA G 120","None","0.53A","3qxvA-5ovwG:21.5","3qxvA-5ovwG:59.57"],["3QXV_A_MTXA2000_1","5uk4","Vicugna pacos","ANTI-VESICULAR STOMATITIS VIRUS N VHH","no annotation",7,"VAL p   2;MET p  34;ARG p  72;ASN p  74;VAL p  79;ALA p  98;TYR p 114","None","0.65A","3qxvA-5uk4p:21.3","3qxvA-5uk4p:71.43"],["3QXV_A_MTXA2000_1","5vaq","Lama glama","NB914","no annotation",6,"ALA B  24;SER B  30;ARG B  72;ASN B  74;VAL B  79;ALA B  98","None","1.02A","3qxvA-5vaqB:22.8","3qxvA-5vaqB:75.00"],["3QXV_A_MTXA2000_1","5vxj","Vicugna pacos","SINGLE-DOMAIN ANTIBODY JMK-E3","no annotation",6,"VAL B   2;MET B  34;ARG B  72;ASN B  74;VAL B  79;ALA B  98","None","0.72A","3qxvA-5vxjB:19.3","3qxvA-5vxjB:63.08"],["3QXV_A_MTXA2000_1","5vxj","Vicugna pacos","SINGLE-DOMAIN ANTIBODY JMK-E3","no annotation",6,"VAL B   2;MET B  34;ARG B  72;VAL B  79;ALA B  98;TYR B 108","None","0.82A","3qxvA-5vxjB:19.3","3qxvA-5vxjB:63.08"],["3QXV_A_MTXA2000_1","5vxl","Vicugna pacos","SINGLE-DOMAIN ANTIBODY JPS-G3","no annotation",7,"ALA B  24;MET B  34;ARG B  73;ASN B  75;VAL B  80;ALA B  99;TYR B 106","None","0.68A","3qxvA-5vxlB:20.2","3qxvA-5vxlB:66.41"],["3QXV_A_MTXA2000_1","5wb1","Human betaherpesvirus 5;Lama glama","ENVELOPE PROTEIN US28, NANOBODY 7 FUSION PROTEIN","no annotation",7,"VAL A1002;ALA A1024;MET A1034;ASN A1073;VAL A1078;ALA A1097;TYR A1107","None","0.97A","3qxvA-5wb1A:18.0","3qxvA-5wb1A:15.08"],["3QXV_A_MTXA2000_1","5y9f","Mus musculus","HEAVY CHAIN OF FAB FRAGMENT OF ANTIBODY 28F10","no annotation",6,"VAL L   2;ALA L  24;MET L  34;ARG L  72;ASN L  74;TYR L 112","None","0.93A","3qxvA-5y9fL:20.1","3qxvA-5y9fL:57.94"],["3QXV_A_MTXA2000_1","5yy5","-","-","no annotation",6,"VAL C   2;ALA C  24;MET C  34;ARG C  71;ASN C  73;TYR C  97","None","0.92A","3qxvA-5yy5C:19.4","3qxvA-5yy5C:undetectable"],["3QXV_A_MTXA2000_1","6apq","Lama glama","ANTI-MARBURGVIRUS NUCLEOPROTEIN SINGLE DOMAIN ANTIBODY B","no annotation",6,"VAL A   2;ALA A  24;ARG A  71;ASN A  73;VAL A  78;TYR A 107","None; CL A 202 ( 4.0A);None;None;None;None","1.19A","3qxvA-6apqA:19.2","3qxvA-6apqA:66.93"],["3QXV_A_MTXA2000_1","6c9w","-","-","no annotation",6,"VAL B   2;ALA B  24;MET B  34;ASN B  74;VAL B  79;TYR B 114","None","1.17A","3qxvA-6c9wB:21.1","3qxvA-6c9wB:undetectable"],["3QXV_A_MTXA2000_1","6d11","Homo sapiens","1450 ANTIBODY, HEAVY CHAIN","no annotation",5,"VAL A   2;MET A  34;ARG A  71;ASN A  73;VAL A  78","None","0.51A","3qxvA-6d11A:20.4","3qxvA-6d11A:44.72"],["3QXV_A_MTXA2000_1","6dbe","Lama glama","NANOBODY VHH R303","no annotation",6,"SER A  30;MET A  34;ARG A  72;VAL A  79;ALA A  98;TYR A 107","None","1.26A","3qxvA-6dbeA:20.6","3qxvA-6dbeA:undetectable"],["3QXV_A_MTXA2000_1","6dbe","Lama glama","NANOBODY VHH R303","no annotation",6,"VAL A   2;ALA A  24;MET A  34;ASN A  74;ALA A  98;TYR A 107","None","1.13A","3qxvA-6dbeA:20.6","3qxvA-6dbeA:undetectable"],["3QXV_A_MTXA2000_1","6dbe","Lama glama","NANOBODY VHH R303","no annotation",6,"VAL A   2;ALA A  24;MET A  34;VAL A  79;ALA A  98;TYR A 107","None","0.81A","3qxvA-6dbeA:20.6","3qxvA-6dbeA:undetectable"],["3QXV_A_MTXA2000_1","6dbe","Lama glama","NANOBODY VHH R303","no annotation",6,"VAL A   2;SER A  30;MET A  34;VAL A  79;ALA A  98;TYR A 107","None","1.01A","3qxvA-6dbeA:20.6","3qxvA-6dbeA:undetectable"],["3QXV_A_MTXA2000_1","6ehg","Lama glama","HC3NB1","no annotation",7,"ALA C  24;MET C  34;ARG C  72;ASN C  74;VAL C  79;ALA C  98;TYR C 112","None","0.71A","3qxvA-6ehgC:22.2","3qxvA-6ehgC:57.14"],["3QXV_A_MTXA2000_1","6gzp","Lama glama","NANOBODY","no annotation",7,"VAL A   2;ALA A  24;MET A  34;ARG A  71;ASN A  73;ALA A  94;TYR A 102","None","0.71A","3qxvA-6gzpA:21.6","3qxvA-6gzpA:undetectable"],["3QXV_A_MTXA2000_1","8fab","Homo sapiens","IGG1-LAMBDA HIL FAB (HEAVY CHAIN)","PF07654(C1-set);PF07686(V-set)",6,"VAL B   2;ALA B  24;MET B  34;ARG B  72;ASN B  74;TYR B 110","None","1.02A","3qxvA-8fabB:21.7","3qxvA-8fabB:59.52"]]